Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries.
We are a multidisciplinary team of biologists, computer scientists, engineers, mathematicians and operators singularly focused on solving an audacious challenge. We take an engineering-first approach to biology.
Immunai launches out of stealth with $20 million in funding, as biotech remains a bright spot in an otherwise turbulent startup ecosystem
Immunai Launches With $20M Seed Funding And Plan To Map The Immune System
We are excited to explore strategic partnerships with academic research institutions, biopharmaceutical companies, and biotechs. to expand the use of our technology and data platform to unlock biological insights, advance novel therapeutic discovery, and accelerate R&D.Contact Us